These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2964490)

  • 1. Suppressor cell activation and enhanced skin allograft survival after tumor promotor but not initiator induced depletion of cutaneous Langerhans cells.
    Halliday GM; Odling KA; Ruby JC; Muller HK
    J Invest Dermatol; 1988 Mar; 90(3):293-7. PubMed ID: 2964490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of suppressor T cells and inhibition of contact hypersensitivity in mice by 12-O-tetradecanoylphorbol-13-acetate and its analogs.
    Kodari E; Pavone A; Reiners JJ
    J Invest Dermatol; 1991 Jun; 96(6):864-70. PubMed ID: 1828476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of tolerance via skin depleted of Langerhans cells by a chemical carcinogen.
    Halliday GM; Muller HK
    Cell Immunol; 1986 Apr; 99(1):220-7. PubMed ID: 2944623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization through carcinogen-induced Langerhans cell-deficient skin activates specific long-lived suppressor cells for both cellular and humoral immunity.
    Halliday GM; Muller HK
    Cell Immunol; 1987 Oct; 109(1):206-21. PubMed ID: 2958141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Langerhans cell migration patterns from sheep skin following topical application of carcinogens.
    Ragg SJ; Dandie GW; Woods GM; O'Connell PJ; Muller HK
    Int J Exp Pathol; 1994 Feb; 75(1):23-8. PubMed ID: 8142271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceptance of class II major histocompatibility complex disparate skin grafts associated with suppressor cells and elevated Langerhans cell numbers.
    Odling KA; Halliday GM; Muller HK
    Pathology; 1992 Jul; 24(3):184-9. PubMed ID: 1437291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of gliotoxin on Langerhans' cell function: contact hypersensitivity responses and skin graft survival.
    McMinn PC; Halliday GM; Muller HK
    Immunology; 1990 Sep; 71(1):46-51. PubMed ID: 1698716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced survival of skin grafts depleted of Langerhans' cells by treatment with dimethylbenzanthracene.
    Odling KA; Halliday GM; Muller HK
    Immunology; 1987 Nov; 62(3):379-85. PubMed ID: 3117676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of benzo[a]pyrene and dimethylbenz[a]-anthracene on Langerhans cell distribution and contact sensitization in murine epidermis.
    Ruby JC; Halliday GM; Muller HK
    J Invest Dermatol; 1989 Feb; 92(2):150-5. PubMed ID: 2493054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical carcinogens and antigens contribute to cutaneous tumor promotion by depleting epidermal Langerhans cells.
    Qu M; Muller HK; Woods GM
    Carcinogenesis; 1997 Jun; 18(6):1277-9. PubMed ID: 9214614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinoic acid protects Langerhans' cells from the effects of the tumour promotor 12-O-tetradecanoylphorbol 13-acetate.
    Halliday GM; Dickinson JL; Muller HK
    Immunology; 1989 Jul; 67(3):298-302. PubMed ID: 2759656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical carcinogens and antigens induce immune suppression via Langerhans' cell depletion.
    Woods GM; Qu M; Ragg SJ; Muller HK
    Immunology; 1996 May; 88(1):134-9. PubMed ID: 8707340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local- and systemic-mediated suppression of contact hypersensitivity in mice by several structurally unrelated classes of tumor promoters.
    Kodari E; Pavone A; Reiners JJ
    Carcinogenesis; 1991 Oct; 12(10):1933-7. PubMed ID: 1934273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitizing capacity of Langerhans' cells obtained from ultraviolet-B-exposed murine skin.
    Dai R; Streilein JW
    Immunology; 1995 Dec; 86(4):661-7. PubMed ID: 8567035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Langerhans cell alterations in cutaneous carcinogenesis.
    Muller HK; Dandie GW; Ragg SJ; Woods GM
    In Vivo; 1993; 7(3):293-6. PubMed ID: 8357973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in cutaneous immune reactivity to dinitrofluorobenzene in graying C57BL/vi.vi mice.
    Rheins LA; Palkowski MR; Nordlund JJ
    J Invest Dermatol; 1986 May; 86(5):539-42. PubMed ID: 3462262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contact hypersensitivity is suppressed after sensitisation by dinitrofluorobenzene of early stage iso-skin grafts.
    Yasuda H; Murayama M; Yamamoto O; Asahi M
    Scand J Plast Reconstr Surg Hand Surg; 1996 Sep; 30(3):169-75. PubMed ID: 8885010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Removal of the majority of epidermal Langerhans cells by topical or systemic steroid application enhances the effector phase of murine contact hypersensitivity.
    Grabbe S; Steinbrink K; Steinert M; Luger TA; Schwarz T
    J Immunol; 1995 Nov; 155(9):4207-17. PubMed ID: 7594576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strain variation in the induction of tolerance by epicutaneous application of trinitrochlorobenzene.
    Sauder DN; Katz SI
    J Invest Dermatol; 1983 May; 80(5):383-6. PubMed ID: 6221052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tumor-promoting agents on density and morphometric parameters of mouse epidermal Langerhans and Thy-1+ cells.
    Baxter CS; Andringa A; Chalfin K; Miller ML
    Carcinogenesis; 1991 Jun; 12(6):1017-21. PubMed ID: 1675159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.